The blockade of TRPV2 is likely to yield interesting findings in the treatment and potentially prevention of cardiomyopathy in patients with muscular dystrophy, though as with all TRPV-related studies, it will be crucial to establish the dose and timing of the modulation of the channel. Here, TRPV2 is linked to cardiomyopathy.